↓ Skip to main content

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers

Overview of attention for article published in Cancer Discovery, May 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news
2 news outlets
blogs
1 blog
twitter
60 tweeters
patent
4 patents

Citations

dimensions_citation
114 Dimensions

Readers on

mendeley
113 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
Published in
Cancer Discovery, May 2018
DOI 10.1158/2159-8290.cd-17-1004
Pubmed ID
Authors

Alexander Drilon, Romel Somwar, Biju P. Mangatt, Henrik Edgren, Patrice Desmeules, Anja Ruusulehto, Roger S. Smith, Lukas Delasos, Morana Vojnic, Andrew J. Plodkowski, Joshua Sabari, Kenneth Ng, Joseph Montecalvo, Jason Chang, Huichun Tai, William W. Lockwood, Victor Martinez, Gregory J. Riely, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Christopher Matheny, Ryma Benayed, Natasha Rekhtman, Marc Ladanyi, Gopinath Ganji

Abstract

NRG1 rearrangements are oncogenic drivers that are enriched in invasive mucinous adenocarcinomas (IMAs) of the lung. The oncoprotein binds ERBB3-ERBB2 heterodimers and activates downstream signaling, supporting a therapeutic paradigm of ERBB3/ERBB2 inhibition. As proof of concept, a durable response was achieved with anti-ERBB3 monoclonal antibody therapy (GSK2849330) in an exceptional responder with an NRG1-rearranged IMA on a phase 1 trial (NCT01966445). In contrast, response was not achieved with anti-ERBB2 therapy (afatinib) in four NRG1-rearranged IMA patients (including the index patient post-GSK2849330). While in vitro data supported the use of either ERBB3 or ERBB2 inhibition, these clinical results were consistent with more profound anti-tumor activity and downstream signaling inhibition with anti-ERBB3 versus anti-ERBB2 therapy in an NRG1-rearranged patient-derived xenograft model. Analysis of 8,984 and 17,485 tumors in The Cancer Genome Atlas and MSK-IMPACT datasets, respectively, identified NRG1 rearrangements with novel fusion partners in multiple histologies, including breast, head and neck, renal, lung, ovarian, pancreatic, prostate, and endometrial cancers.

Twitter Demographics

The data shown below were collected from the profiles of 60 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 113 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 113 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 27 24%
Other 11 10%
Student > Bachelor 8 7%
Student > Ph. D. Student 7 6%
Student > Master 7 6%
Other 23 20%
Unknown 30 27%
Readers by discipline Count As %
Medicine and Dentistry 31 27%
Biochemistry, Genetics and Molecular Biology 23 20%
Agricultural and Biological Sciences 10 9%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Unspecified 2 2%
Other 5 4%
Unknown 36 32%

Attention Score in Context

This research output has an Altmetric Attention Score of 63. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 September 2022.
All research outputs
#545,696
of 22,132,418 outputs
Outputs from Cancer Discovery
#274
of 3,541 outputs
Outputs of similar age
#13,722
of 299,581 outputs
Outputs of similar age from Cancer Discovery
#9
of 70 outputs
Altmetric has tracked 22,132,418 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,541 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.9. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 299,581 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 70 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.